key: cord-0257917-yataraz5
authors: Taetzsch, Thomas; Shapiro, Dillon; Eldosougi, Randa; Myers, Tracey; Settlage, Robert; Valdez, Gregorio
title: The microRNA, miR-133b, functions to slow Duchenne muscular dystrophy pathogenesis
date: 2020-03-20
journal: bioRxiv
DOI: 10.1101/2020.03.19.988519
sha: 70ae9e5733db54f87715a957b99b9b88dab221f5
doc_id: 257917
cord_uid: yataraz5

Duchenne muscular dystrophy (DMD) is characterized by progressive degeneration of skeletal muscles. To date, there are no treatments available to slow or prevent the disease. Hence, it remains essential to identify molecular factors that promote muscle biogenesis since they could serve as therapeutic targets for treating DMD. While the muscle enriched microRNA, miR-133b, has been implicated in the biogenesis of muscle fibers, its role in DMD remains unknown. To assess the role of miR-133b in DMD-affected skeletal muscles, we genetically ablated miR-133b in the mdx mouse model of DMD. In the absence of miR-133b, the tibialis anterior muscle of juvenile and adult mdx mice is populated by small muscle fibers with centralized nuclei, exhibits increased fibrosis, and thickened interstitial space. Additional analysis revealed that loss of miR-133b exacerbates DMD-pathogenesis partly by altering the number of satellite cells and levels of protein-encoding genes, including previously identified miR-133b targets as well as genes involved in cell proliferation and fibrosis. Altogether, our data demonstrate that skeletal muscles utilize miR-133b to mitigate the deleterious effects of DMD.

Duchenne muscular dystrophy (DMD) is the most prevalent of the muscular dystrophies, primarily affecting boys, with symptoms arising between 3-5 years of age. While advances in medical care have allowed DMD patients to live into adulthood, there is still no cure for the disease [1] . DMD is caused by loss of function of the dystrophin gene, an X-linked gene important for maintaining the integrity of the muscle fiber sarcolemma [1] [2] [3] [4] through its association with dystroglycan and sarcoglycans [2, 5, 6] . While the initial formation of skeletal muscles proceeds mostly unimpeded during development, muscle fibers rapidly degenerate as individuals mature due to damages on the peripheral membrane caused by mechanical stress associated with muscle contraction [1, 2] . As the disease becomes more severe, skeletal muscle progenitor cells, known as satellite cells, fail to adequately proliferate and differentiate in order to replace damaged muscle fibers [7] . DMD-pathogenesis is further exacerbated by chronic immune cell infiltration and fibrosis [8, 9] that results from deposition of collagens and fat emanating from fibroblasts and adipocytes [7, 10, 11] . These pathological changes invariably impair the function and stability of remaining muscle fibers, compromising voluntary movements and ultimately causing death of affected individuals [1] . Thus, it is important to continue to explore new avenues for treating DMD.

3

The progressive nature of DMD [1] suggests that endogenous mechanisms could be recruited to mitigate damages caused by DMD and to maintain the regenerative capacity of skeletal muscles. Arguably, the most attractive endogenous molecular mechanisms would be those that bolster the regenerative capacity of skeletal muscles and endow muscle fibers with the ability to overcome fibrosis and inflammation resulting from the loss of dystrophin [12] . In this regard, microRNAs have received attention as candidate molecules for modifying DMD-pathology because of their functions in normal and disease-affected skeletal muscles and the relative ease with which they can be packaged into vectors [13] [14] [15] [16] . These ubiquitous small non-coding RNAs are approximately 22 nucleotides in length and impact a wide range of cellular processes by inhibiting translation of target mRNAs [17, 18] .

There is ample evidence suggesting that the muscle-enriched microRNA, miR-133b, may be a candidate for modifying DMD-pathogenesis. In vitro studies have shown that targeting miR-133b and its close relative, miR-133a, affect different stages of myogenesis, including the proliferation of satellite cells [19, 20] and myoblasts [21] , the differentiation of satellite cells into either myoblasts or brown adipose tissue [22] , and the formation of muscle fibers [20, 23, 24] . In vivo, published data indicate that skeletal muscles upregulate miR-133b during regeneration following injury [25] and may utilize miR-133b to maintain homeostasis during cellular, functional and biochemical changes induced by exercise [26] and denervation [27] as well as in sarcopenia [28] . Additionally, miR-133b was shown to accelerate muscle regeneration following injury in young adult rats alongside miR-1 and miR-206 [29] . Importantly, there is evidence indicating that miR-133 is elevated in DMD patients, however this study did not distinguish miR-133b from miR-133a [30] . Despite these findings, the role of miR-133b in DMD remains unclear. This is because miR-133b has yet to be examined independently of other non-coding RNAs in DMD [31, 32] . In one published study, miR-133b was proposed to collaborate with a long noncoding RNA, linc-MD1, to affect the timing and rate of muscle fiber formation in DMD [31] . In another study, it was shown that simultaneously deleting miR-133b and miR-206, another muscle enriched microRNA found in the same long non-coding RNA as miR-133b, has no effect on DMD pathogenesis in dystrophin-null (mdx) mice [32] . Therefore, it remains unknown if and how miR-133b plays a role in DMD.

To directly test the role of miR-133b in DMD-pathogenesis, we generated mdx mice lacking miR-133b. Analysis of these mice during various stages of disease severity revealed that miR-133b does in fact play important roles in DMD. Loss of miR-133b decreased the size of muscle fibers while increasing fibrosis in mdx mice. These changes are partly due to alterations in satellite cell abundance and changes in expression of a myriad of genes, including both known targets of miR-133b and genes shown to be involved in cell cycle regulation and promotion of fibrosis. Altogether, these findings strongly suggest that skeletal muscles increase miR-133b levels to mitigate damages caused by DMD.

Although miR-133 is elevated in the serum of DMD patients [30] , it remains unknown if this is due to increased expression of miR-133b, miR-133a, or both. Additionally, the temporal relationship between miR-133b levels and severity of DMD in skeletal muscles remains unknown. To answer these questions, we examined miR-133b expression during the initial stage, postnatal day 30 (p30), and severe stage (p60), of the disease in the tibialis anterior (TA) muscle of mdx mice [33] . Since one nucleotide distinguishes mature miR-133b from miR-133a, we examined levels of pre-miRNAs instead of mature miRNAs, using qPCR. This analysis revealed that miR-133b is increased at p30 and p60 in mdx mice compared to control mice (Fig. 1A) . Interestingly, miR-133b expression in mdx mice is significantly lower at p60 compared to p30. Thus, miR-133b levels are inversely correlated with the severity of the disease; highest at p30 and lowest at p60. This expression pattern was specific to miR-133b compared to miR-133a, which was expressed at similar or lower levels in mdx muscle (Fig. 1B) .

It also differed from other muscle-enriched microRNAs in mdx mice. While miR-206 was Levels of precursor (A) miR-133b and (B) miR-133a in the TA muscle of juvenile (p30) and adult (p60) control and mdx mice were assessed using qPCR. All values reported as mean ± SEM; p30, n = 4; p60 n = 3. * p < 0.05 versus p30 control, # p < 0.05 versus p60 control, † p < 0.05 versus p30 mdx. N.D. not detected. significantly higher at both ages in mdx mice, it is expressed at higher levels at p60 compared to p30 in mdx mice (Fig. s1A ) unlike miR-133b, which is lower at p60 compared to p30 in mdx mice.

Levels of miR-1 were similar at p30 and somewhat decreased at p60 in the TA muscle of mdx mice compared to control mice (Fig. s1B) , confirming previous reports [34] .

To date, the role of miR-133b in DMD pathogenesis remains debated mainly because it has yet to be examined independently of the precursor long-noncoding RNA in which both miR-133b and miR-206 are encoded (LINCMD1) [16, 35] . Previous work has demonstrated directly opposing myogenic functions of miR-206, miR-133b and other regions of the LINCMD1 gene [31] . While deletion of miR-206 alone exacerbates DMD-related pathology [25] , the simultaneous deletion of mir-133b and miR-206 has no effect on it [32] . To examine the function of miR-133b independently of miR-206 in DMD, we used mice lacking only miR-133b (miR-133b -/-). First, we examined muscles only lacking miR-133b in otherwise healthy young adult mice. We found that deletion of miR-133b does not cause obvious changes in skeletal muscles. There is no difference in the average muscle fiber cross-sectional area (CSA , Fig s2 A ,B,D), distribution of muscle fiber size ( Fig. s2 C) , mononucleated cells occupying the interstitial space ( Fig. s2 E) , and number of Pax7 + satellite cells (Fig. s2 F) between miR-133b +/+ and miR-133b -/mice. In stark contrast, deletion of miR-133b from mdx mice, following crossing of miR-133b null with mdx mice (herein referred to as mdx; miR-133b -/-), exacerbated DMD-related pathological features in skeletal muscles. Analysis of muscle fibers in the TA muscle of juvenile (p30) mice revealed a decrease in the muscle fiber CSA in mdx; miR-133b -/mice as compared to mdx; miR-133b +/+ (Figure 2 A,B,D). This reduction in muscle fiber CSA is due to fewer muscle fibers with large CSAs and more muscle fibers with small CSAs (Figure 2 A-C). As expected, the CSA of the entire TA muscle also decreased in mdx; miR-133b -/mice compared to mdx; miR-133b +/+ mice (Figure 2 E) .

Interestingly, the number of muscle fibers with centralized nuclei, a characteristic of regenerating juvenile and adult muscle fibers, was lower in mdx; miR-133b -/muscle however this difference was not statistically significant (Figure 2 F). Altogether, these data suggest that miR-133b affects the initial progression of DMD by altering the maturation and not the rate of muscle fiber degeneration and regeneration in mdx mice.

We next assessed the effect of deleting miR-133b in mdx mice during stages of severe (p60) and plateauing (p90) DMD pathology [33] . At P60, the average muscle fiber and overall TA 6 CSA was similar between mdx littermates with and without miR-133b (Figure 3 A,B,D,E).

However, a frequency distribution analysis revealed significantly more muscle fibers with very small CSAs in the TA muscle of mdx; miR-133b -/mice (Figure 3 C) . Additionally, the incidence of muscle fibers with centralized nuclei was significantly higher in mdx; miR-133b -/mice ( Figure   3F ). Thus, the continued presence of small muscle fibers, along with an increased number of regenerating fibers, demonstrates that loss of miR-133b also exacerbates DMD-related pathology at p60, when the disease is most severe in mdx mice. These differences between mdx; miR-133b -/and mdx; miR-133b +/+ muscle are mostly missing at p90, an age when muscle fibers have partly adapted to loss of dystrophin and exhibit less DMD-related pathology [33] . While the number of regenerating fibers remains slightly elevated in mdx; miR-133b -/muscle (Figure s3 F, p = 0.06), were similar between mdx; miR-133b -/and mdx;miR-133b +/+ littermates at p90.

Although we previously showed that neuromuscular junctions (NMJs) are unaffected in miR-133b null mice [27] , it is possible that NMJs afflicted with DMD require miR-133b. To address this possibility, we examined NMJs in the extensor digitorum longus (EDL) muscle of mdx; miR-133b -/mice following staining for nicotinic acetylcholine receptors (nAChRs) with fluorescently-tagged alpha-bungarotoxin (fBTX). This analysis showed that loss of miR-133b resulted in diminished nAChR area ( Fig. s4 A 

Fibrosis and inflammation are prominent features of DMD pathology, and contribute to progressive loss of myofibers and muscle weakness [9, 10] . We thus asked if loss of miR-133b exacerbates DMD by increasing fibrosis and the number of cells occupying the interstitial space staining in cross-sections of the TA muscle was used to assess the area of the interstitial space as a proxy for fibrosis in mdx; miR-133b +/+ and mdx; miR-133b -/mice. (C) Increased laminin + interstitial area was observed in p30 mdx; miR-133b -/versus mdx; miR-133b +/+ TA muscle. (D) DAPI + nuclei within the interstitial space were analyzed as a measurement of infiltrating cells. Increased numbers of nuclei within the interstitial space were observed in p30 mdx; miR-133b -/-TA muscle. (E-G) At p60, a similar trend of increased laminin + interstitial area and (H) increased interstitial nuclei was observed in mdx; miR-133b -/-TA muscle. (I-K) At p90 interstitial area and (L) interstitial nuclei were similar in mdx; miR-133b -/and mdx; miR-133b +/+ TA muscle. All values reported as mean ± SEM, n = 3. * p < 0.05, scale bar = 50 µm.

. of skeletal muscle. We measured the area of the interstitial space in the TA muscle of p30 mdx; miR-133b +/+ and mdx; miR-133b -/mice by tracing the laminin-positive region separating muscle fibers. This analysis showed a marked increase in the interstitial space in mdx; miR-133b -/compared to mdx; miR-133b +/+ mice ( Fig. 4A-C) . We then counted the number of nuclei residing in the interstitial space as a rough measurement of infiltrating cells. We found that the number of nuclei occupying the interstices of myofibers is more than two-fold higher in the TA muscle of mdx; miR-133b -/compared to mdx; miR-133b +/+ mice (Fig. 4D ). We extended these analyses to P60 mice and found a similar trend with a roughly two-fold increase in the area of laminin positive staining ( Fig. 4E -G) and twice as many nuclei (Fig. 4H ) in P60 mdx; miR-133b -/compared to mdx; miR-133b +/+ littermates. These results show that deletion of miR-133b exacerbates DMDpathogenesis partly by increasing fibrosis and the number of mononucleated cells in the interstitial space, two cellular changes shown to be associated with diminished health of muscle fibers. The increased presence of mononucleated cells in the interstitial space may be indicative of an elevated presence of inflammatory cells, which typically infiltrate DMD muscle tissue [9] . Once again, we found that deleting miR-133b at p90 did not further exacerbate fibrosis and accumulation of mononucleated cells in the interstitial space ( Fig. 4 I-L) . These findings indicate that other mechanisms override the effect of deleting miR-133b and the loss of dystrophin around p90 in mdx mice. 

In vitro studies have uncovered important roles for miR-133b in satellite cell proliferation and differentiation [14, 36] , raising the possibility that loss of miR-133b exacerbates DMDpathogenesis by affecting satellite cells. To address this possibility, we examined the number of Pax7 + satellite cells in the TA muscle of p30, p60 and p90 mdx; miR-133b +/+ and mdx; miR-133b -/mice. At p30, the number of Pax7 + satellite cells was slightly elevated in mdx; miR-133b -/as compared to mdx; miR-133b +/+ muscle (Fig. 5 A,C,D) . However as the disease progressed, the number of Pax7 + satellite cells decreased at a faster rate in mdx; miR-133b -/compared to mdx; miR-133b +/+ muscle at both p60 (Fig. 5 B ,C,E) and p90 ( Fig. 5C and s5) . These results show that miR-133b affects DMD-pathogenesis by altering the number of satellite cells.

The results above, showing that deletion of miR-133b exacerbates DMD-pathogenesis, raised the prospect that miR-133b also plays a critical role in the repair of skeletal muscles affected by other stressors. We thus asked if miR-133b must be present for muscle fibers to regenerate properly and in a timely fashion following an acute injury. For this, we administered cardiotoxin (CTX), which causes muscle fibers to rapidly degenerate [37, 38] , to the TA muscle of miR-133b +/+ and miR-133b -/littermates. As muscle fibers begin to reform, around 7 days (7d) post-CTX injection, the average muscle fiber CSA was lower and there were fewer muscle fibers with larger CSAs in miR-133b -/as compared to miR-133b +/+ mice ( Fig. 6 A,B,E). By 14d post-CTX injection, there was a slight increase in the number of fibers with very small CSAs (<200 µm 2 ) and fewer muscle fibers with CSAs that are typical of fully regenerated muscle (i.e. >2200 um 2 ) in miR-133b -/as compared to miR-133b +/+ muscle (Fig. 6 C,D,F) . These changes led to a net reduction in the average muscle fiber CSA in miR-133b -/mice (Fig. 6 G) and demonstrate that regenerated muscle fibers mature at a slower rate in the absence of miR-133b. These differences do not appear to result from changes in the interstitial space since the number of nuclei was similar in miR-133b -/versus miR-133b +/+ muscle at both 7d and 14d post-CTX (Fig. 6H) . The slower rate of muscle fiber regeneration also does not seem to be caused by a lower abundance of Pax7 + satellite cells (Fig. 6I and Fig. s6) . Thus, miR-133b does not have an obvious impact on satellite cells and other mononucleated cells in the interstitial space in transiently stressed skeletal muscles. This is in stark contrast to chronically stressed skeletal muscles in mdx mice, where miR-133b must be present to minimize the accumulation of pathological features. 

To determine if loss of miR-133b directly impacts satellite cell proliferation and their ability to generate new myofibers, we isolated and cultured satellite cells from p15-p20 miR-133b +/+ and miR-133b -/littermates at low density. After 72 h in vitro, Pax7 + satellite cells lacking miR-133b proliferated faster compared to miR-133b +/+ controls (Fig. 7 A-C) . To determine 13 whether miR-133b impacts satellite cell differentiation and fusion into myotubes, we seeded satellite cells at a high density and treated with differentiation media. At both 2 (Fig. 7 D,E) and 5 (Fig. 7 F,G) days post-differentiation we observed smaller myosin + myotubes in miR-133b -/versus miR-133b +/+ cultures (Fig. 7 H) , suggesting an impairment of myotube formation in the absence of miR-133b. Taken together, these results show that miR-133b functions to control satellite cell proliferation and formation of myofibers, which are two cellular processes altered in in mdx; miR-133b -/muscle.

The increased DMD-pathogenesis in mdx; miR-133b -/mice indicates that miR-133b impacts expression of protein-coding genes with important functions in DMD-afflicted skeletal muscles. To identify genes altered in the TA muscle lacking miR-133b, we compared the transcriptome between wild type, miR-133b -/-, mdx; miR-133b +/+ , and mdx; miR-133b -/mice using RNA seq. Genes with an absolute log fold change greater than 1 and adjusted p-value less than 0.01 were deemed differentially expressed between genotypes. This analysis revealed the following: 1) there are very few genes differentially expressed between miR-133b +/+ and miR-133b -/mice (Fig. 8A) , partly corroborating cellular analysis showing that loss of miR-133b has no obvious effect on otherwise healthy skeletal muscles (Fig. s2) and NMJs [27] ; 2) a myriad of genes are significantly altered in the TA muscle of mdx compared to wild type control mice (Fig.   8 B) ; 3) deletion of miR-133b further alters the transcriptome of the TA muscle in mdx mice (Fig.   8C ).

To gain insights into the signaling pathways miR-133b alters to exacerbate DMDpathology in mdx mice, we used Ingenuity Pathway Analysis (IPA). This revealed several pathways with particular relevance to DMD pathogenesis that were closely associated with deletion of miR-133b in mdx mice (Fig. 8D) including STAT3, Apelin, and IL-6. STAT3 has been shown to be expressed by satellite cells where it plays a pivotal role in myogenesis by promoting satellite cell proliferation and inhibiting the formation of myotubes [39] . Recent studies have demonstrated that. IL-6 is closely associated with infiltrating cells of the interstitial space and is downregulated in response to glucocorticoid treatment in DMD patients [39] . Apelin has been characterized as an exercised-induced signaling molecule that prevents sarcopenia, improves muscle regeneration, and decreases inflammation in aging muscle [40] . Modulation of these pathways by miR-133b may serve to protect muscle from DMD pathogenesis.

Prominent among genes upregulated in mdx; miR-133b -/muscle were a number of known miR-133b targets that were identified using miRTarBase [41] that have also been shown to be involved in TGF-B signaling and DMD pathology (Table 1) . These included RhoA, a well characterized target of miR-133b [42] that is associated with myoblast fusion, muscle regeneration, fatty infiltration and effectiveness of glucocorticoid treatment in mdx mice [43] [44] [45] [46] [47] . A number of other genes related to TGF-β signaling that are not presently known to be direct miR-133b targets were also upregulated in mdx; miR-133b -/muscle, including the TGF-β receptor, TGF-β-induced factor homeobox 1 (TGIF1), SMAD3, and SMAD5 (Table 2) [48, 49] . In addition, latent TGF-β binding protein 4 (LTBP4), a protein that is responsible for sequestering TGF-β in the extracellular matrix, and one of a handful of genes known to affect disease progression in DMD patients [50, 51] , was downregulated in mdx; miR-133b -/muscle. Overall, this expression dataset supports important roles for miR-133b in mitigating DMD pathogenesis. It also provides promising candidates, in the form of specific genes and signaling modules, that could be directly targeted to attenuate the various pathological features associated with DMD.

This is the first study to directly assess the role of miR-133b on DMD pathogenesis and on the regenerative capacity of skeletal muscle in vivo. We show that deletion of miR-133b reduces the size of muscle fibers and increases fibrosis in mdx mice. Importantly, we provide cellular and molecular mechanistic insights on how miR-133b impacts DMD pathogenesis. We demonstrate that deletion of miR-133b alters the number of satellite cells and their ability to form myofibers.

We also uncover a myriad of genes and signaling modules that are altered when miR-133b is deleted in mdx mice. Altogether, our findings provide the basis to use miR-133b and downstream targets to augment the regenerative capacity of skeletal muscles possibly through satellite cells, and to reduce fibrosis and infiltration of mononucleated cells to treat DMD.

The impact of miR-133b on satellite cells is a significant finding in this study because of the role these cells play in the progression of DMD pathogenesis. Specifically, it is clear that satellite cell dysfunction contributes to the loss of skeletal muscle mass and increased presence of fibrotic and adipose tissue that accompanies the progression of DMD [11, 12] . We show that miR-133b plays an important role in modulating the number of satellite cells and their capacity to generate myofibers in DMD. Without miR-133b, satellite cells were more numerous during the initial stages of DMD but then significantly decreased with disease progression in mdx mice. These changes in satellite cell numbers were accompanied by an increase in the number of small myofibers during the early and severe stages of the disease in mdx mice. In culture, we found that miR-133b deletion resulted in elevated satellite cell proliferation and inhibited myotube formation.

These in vitro findings suggest that a central role of miR-133b in satellite cells is to decrease the duration of satellite cell activation by promoting not only differentiation but also quiescence.

Hence, one possible explanation for the initial increase and subsequent decrease in satellite cell numbers at p30 and p60, respectively, in mdx;miR-133b -/mice is that deletion of miR-133b results in depletion of the quiescent satellite cell pool that is necessary to maintain the satellite cell population as the disease progresses. Thus, in the absence of miR-133b, there are initially more satellite cells at the onset of the disease as satellite cells favor proliferation over both quiescence and differentiation. However, over time, a preference for activation ultimately depletes the quiescent satellite cell pool which in turn causes an overall decrease in newly generated activated satellite cells and an insufficient regenerative response to muscle fiber damage. Irrespective, these data add to published studies indicating that miR-133b plays important roles in satellite cell proliferation and commitment to myoblasts. Thus, the varying levels of miR-133b at specific stages of DMD severity in mdx muscle (i.e. p30 and p60) may be necessary to both control the proliferation and differentiation of satellite cells to promote regeneration of muscle fibers.

In contrast to mdx mice, deletion of miR-133b from healthy control mice had a limited effect on skeletal muscles. Muscle fiber size, satellite cell number, ECM thickness, and levels of infiltrating cells were normal in healthy muscle lacking miR-133b. While over 600 genes were differentially regulated in mdx muscle in the absence of miR-133b, RNA seq analysis identified only two differentially regulated genes related to deletion of miR-133b in healthy muscle. These findings are in line with previous studies demonstrating that miRNAs are primarily utilized by cells in mature tissues to coordinate responses under stress [14, 26, 52, 53] . It also supports our findings that miR-133b is utilized by activated satellite cells, which are limited in number in healthy skeletal muscle. In addition to impacting DMD pathogenesis, we found that deletion of miR-133b slows the rate of muscle fiber regeneration following cardiotoxin-induced injury.

However, it must be noted that the number of satellite cells was similar between miR-133b +/+ and miR-133b -/skeletal muscles following cardiotoxin-induced injury. This could be due to the earliest time point at which we examined satellite cells (7d post-CTX), which does not represent the peak of proliferation [54] . Alternatively, it may indicate that miR-133b plays a role in ensuring the continuous proliferation of satellite cells during chronic, asynchronous muscle regeneration and is not necessary for repair of transiently stressed muscle fibers.

In addition to orchestrating muscle regeneration, this study demonstrates an additional and previously unknown role for miR-133b in mitigating fibrosis in DMD muscle. Global deletion of miR-133b enhanced the severity of DMD-associated fibrosis, as seen by increased interstitial space and infiltration of cells within it. While elevated fibrosis may be directly related to dysregulated satellite cell proliferation and impaired myofiber formation, it is possible that miR-133b may directly regulate fibroblasts, adipocytes, immune cells, and other cells residing in skeletal muscles.

Several lines of evidence support roles for miR-133b in other types of muscle resident cells.

Previous work has demonstrated that miR-133 blocks adipogenesis in skeletal muscle tissue [22] .

Our RNA seq study identified alterations in the expression of a number of genes related to inflammation and fibrosis in mdx; miR-133b-/-muscle, including TGF-B pathway members such as SMAD3, LTBP4, and TGFBR. In addition, IPA identified cell signaling associated with the inflammatory cytokine IL-6 to be prominently affected by deletion of miR-133b from mdx muscle.

The therapeutic relevance of IL-6 has been demonstrated by a recent study showing that a reduction in IL-6 is associated with improved outcomes associated with steroid treatment in DMD patients [39] .

Loss of satellite cells, inability to reform muscle fibers, fibrosis, and accumulation of mononucleated cells in the interstitial space are hallmarks of DMD pathology. These cellular and molecular features inevitably contribute to progressive loss of muscle fibers, muscle weakness, and death. Hence, it is critical to continue to identify targets that could slow these features of DMD.

Our results provide evidence that miR-133b, a short oligonucleotide, could be used to mitigate DMD pathology by augmenting the proliferation and differentiation of satellite cells while reducing inflammation and fibrosis. We also identified a myriad of candidate genes that may also be attractive therapeutic targets in DMD. Thus, future experiments will assess the impact of manipulating miR-133b levels and the action of downstream targets at specific stages of DMD pathology.

Dystrophin-null DMD mice (mdx, Jackson Labs 001801 [55] ) were purchased from Jackson Laboratories (Bar Harbor, Maine). miR-133b -/mice were obtained from the Feng lab [56] . Wildtype control mice used for qPCR were on a mixed genetic background and were age and sexmatched to mdx mice. miR-133b -/mice were crossed with mdx mice to generate mdx; miR-133b -/mice on a mixed genetic background. Male mice were used for all comparisons of mdx; miR-133b +/+ with mdx; miR-133b -/-. Male and female mice were used for assessing deletion of miR- are not immediately adjacent to the laminin positive staining. The fractionator method [58] was used to randomly sample an average of 290 muscle fibers per muscle. To achieve this, a grid was superimposed on the images with ImageJ software and all muscle fibers located on a grid point were selected for measurement. Muscle fiber CSA measurements were performed with ImageJ.

Interstitial nuclei counts were performed on laminin/DAPI stained 16 µm TA cross sections using the fractionator sampling method. On average, 30 regions measuring 7800 µm 2 were randomly sampled across two cross sections collected from the medial TA. Interstitial nuclei were identified as DAPI positive nuclei located in areas of thickened laminin deposition in the interstitial space and not immediately adjacent to muscle fibers. Counting and sampling were performed on blinded images with ImageJ software.

Fibrosis analysis was performed on laminin/DAPI stained 16 µm thick TA cross sections using the fractionator sampling method. On average, 22 regions measuring 20,000 µm 2 were randomly sampled across two cross sections collected from the medial TA. Interstitial area was identified by the presence of thick laminin staining occupied by nuclei in the interstices of muscle fibers.

Sampling and measurements were obtained from blinded images with ImageJ software and reported as a percent of the total cross-sectional area sampled.

Counting of Pax7+ satellite cells was performed on blinded images obtained from Pax7/laminin/DAPI stained TA cross sections of 16 µm thickness using the fractionator sampling method. Four cross sections were selected from the medial TA at 0.3 mm intervals. Pax7+ cells were identified by the presence of a Pax7+/DAPI+ nucleus located immediately adjacent to a laminin+ muscle fiber.

Satellite cell proliferation analysis was performed on blinded images of satellite cell enriched cultures using the fractionator sampling method. Following muscle dissociation from a single mouse, cells were seeded to two chamber slides. The first slide was fixed immediately after the cells attached to the slide (4-16 h post-seed) and the second slide was fixed at 72 h post-seed. The cell cultures were stained with Pax7/DAPI, imaged, and satellite cells were identified by the presence of a Pax7+/DAPI+ nucleus. One replicate represents 3 technical replicates derived from the dissociation of skeletal muscles of a single miR-133b +/+ mouse or its miR-133b -/littermate.

Data are presented as the average fold change in the number of Pax7+ cells at 72 h post-seed relative to the number of Pax7+ cells immediately after seeding for a given replicate.

Myotube size analysis was performed on blinded images of primary muscle cultures derived from miR-133b +/+ and miR-133b -/littermates that were fixed at 2 or 5 d post-differentiation and stained with myosin/DAPI. Myotubes were identified by the presence of myosin and at least two nuclei.

Area measurements were obtained by outlining the myosin + area of a myotube using ImageJ software.

Cardiotoxin from Naja melanoleuca (#v9000, Sigma-Aldrich, St. Louis, MO) was diluted in sterile PBS to a final concentration of 70 µg/mL. Following general anesthesia of p60 miR-133b +/+ and miR-133b -/littermates with ketamine (50 mg/kg IP), 50 µL of cardiotoxin solution was delivered to the belly of the TA muscle with a 31 gauge needle.

Hindlimb muscles were collected from p15-p21 miR-133b +/+ and miR-133b -/littermates. After removal of connective tissue and fat, muscles were cut into 5 mm 2 pieces with forceps and digested in 2 mg/mL collagenase II (Worthington Chemicals, Lakewood, NJ) for 1h at 37 o C. Muscles were further dissociated by mechanical trituration in high glucose Dulbecco's modified eagle medium (DMEM, #11965118, Life Technologies, Carlsbad, CA) containing 10% horse serum (Life Technologies #16050122) and passed through a 40 µm filter to generate a single cell suspension.

Excess debris was removed from the suspension by centrifugation in 4% BSA followed by a Table 3 . RNA sequencing was performed by the Genomics Sequencing Center at Virginia Tech using an mRNA-stranded Seq library prep (Illumina, San Diego, CA) and NextSeq High Output 75SR sequencing (Illumina, San Diego, CA).

Following sequencing, data were trimmed for both adaptor and quality using a combination of eautils and Btrim [59, 60] . Sequencing reads were aligned to the genome using Tophat2/HiSat [61] and counted via HTSeq [62] . QC summary statistics were examined to identify any problematic samples (e.g. total read counts, quality and base composition profiles (+/-trimming), raw fastq formatted data files, aligned files (bam and text file containing sample alignment statistics), and count files (HTSeq text files). Following successful alignment, mRNA differential expression was determined using contrasts of and tested for significance using the Benjamini-Hochberg corrected Wald Test in the R-package DESeq [63] . Signaling pathway analysis was generated through the use of IPA (QIAGEN Inc., https://www.qiagenbio-informatics.com/products/ingenuity-pathwayanalysis).

Statistical analysis Independent Welch's or Student's T-tests were used to make comparisons between 2 means. Oneway ANOVA with Bonferroni post-hoc analysis was used to make comparisons between 3 or more means. Statistical analyses performed with the Microsoft Excel Data Analysis plugin and R software. Data are expressed as mean ± SEM. A value of P < 0.05 was considered statistically significant.

The Pathogenesis and Therapy of Muscular Dystrophies

Muscle Diseases: The Muscular Dystrophies

Dystrophin: The protein product of the duchenne muscular dystrophy locus

The dystrophin complex forms a mechanically strong link between the sarcolemma and costameric actin

Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix

Molecular circuitry of stem cell fate in skeletal muscle regeneration, ageing and disease

Macrophage plasticity and the role of inflammation in skeletal muscle repair

Immune-mediated pathology in Duchenne muscular dystrophy

oz-C??noves, Understanding the process of fibrosis in duchenne muscular dystrophy

Satellite cells and the muscle stem cell niche

Satellite Cells in Muscular Dystrophy -Lost in Polarity

Mega roles of microRNAs in regulation of skeletal muscle health and disease

Muscle-specific microRNAs in skeletal muscle development

Non-coding RNAs in muscle differentiation and musculoskeletal disease

MicroRNA control of muscle development and disease

Argonaute proteins: functional insights and emerging roles

Regulation of microRNA biogenesis

The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation

Wnt/β-catenin signaling induces the myomiRs miR-133b and miR-206 to suppress Pax7 and induce the myogenic differentiation program

A feedback circuit between miR-133 and the ERK1/2 pathway involving an exquisite mechanism for regulating myoblast proliferation and differentiation

MicroRNA-133 Controls Brown Adipose Determination in Skeletal Muscle Satellite Cells by Targeting Prdm16

Muscle-specific microRNA miR-206 promotes muscle differentiation

A feedback circuit between miR-133 and the ERK1/2 pathway involving an exquisite mechanism for regulating myoblast proliferation and differentiation

MicroRNA-206 promotes skeletal muscle regeneration and delays progression of Duchenne muscular dystrophy in mice

Regulation of miRNAs in human skeletal muscle following acute endurance exercise and short-term endurance training

The role of muscle microRNAs in repairing the neuromuscular junction

Expression Patterns of Muscle -Specific miR -133b and miR -206 Correlate with Nutritional Status and Sarcopenia

Acceleration of muscle regeneration by local injection of muscle-specific microRNAs in rat skeletal muscle injury model

Bozzoni, miRNAs as serum biomarkers for Duchenne muscular dystrophy

A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA

The miR-206/133b cluster is dispensable for development, survival and regeneration of skeletal muscle

Age-related changes in replication of myogenic cells in mdx mice: quantitative autoradiographic studies

Expression Analysis in Multiple Muscle Groups and Serum Reveals Complexity in the MicroRNA Transcriptome of the mdx Mouse with Implications for Therapy

miRNAS in normal and diseased skeletal muscle

microRNAs in skeletal muscle development

Proceedings: Light and electron microscopic changes in mouse muscle fibres and motor end-plates caused by the depolarizing fraction (cardiotoxin) of the of the venom of Dendroaspis jamesoni

Changes in motor end-plates resulting from 27 muscle fibre necrosis and regeneration. A light and electron microscopic study of the effects of the depolarizing fraction (cardiotoxin) of Dendroaspis jamesoni venom

STAT3 in skeletal muscle function and disorders

The exerkine apelin reverses age-associated sarcopenia

MiRTarBase: A database curates experimentally validated microRNA-target interactions

MicroRNA-133b is a key promoter of cervical carcinoma development through the activation of the ERK and AKT1 pathways

RhoA mediates defective stem cell function and heterotopic ossification in dystrophic muscle of mice

RhoA/ROCK inhibition improves the beneficial effects of glucocorticoid treatment in dystrophic muscle: implications for stem cell depletion

Skeletal muscle differentiation and fusion are regulated by the BAR-containing Rho-GTPaseactivating protein

Signaling mechanisms in mammalian myoblast fusion

Degenerative muscle fiber accelerates adipogenesis of intramuscular cells via RhoA signaling pathway

Role of TGF-β signaling in inherited and acquired myopathies

United Dystrophinopathy Project, LTBP4 genotype predicts age of ambulatory loss in Duchenne muscular dystrophy

AMPK Activation Regulates LTBP4-Dependent TGF-β1 Secretion by Pro-inflammatory Macrophages and Controls Fibrosis in Duchenne Muscular Dystrophy

MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice

Hornstein, miRNAs at the interface of cellular stress and disease

Inefficient skeletal muscle repair in inhibitor of differentiation knockout mice suggests a crucial role for BMP signaling during adult muscle regeneration

X chromosome-linked muscular dystrophy (mdx) in the mouse

Normal Midbrain Dopaminergic Neuron Development and Function in miR-133b Mutant Mice

Thyroid Hormone Transporters MCT8 and OATP1C1 Control Skeletal Muscle Regeneration

Unbiased stereology : a concise guide

Comparison of Sequencing Utility Programs

Btrim: A fast, lightweight adapter and quality trimming program for nextgeneration sequencing technologies

HISAT: a fast spliced aligner with low memory requirements

HTSeq--a Python framework to work with highthroughput sequencing data

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

Myogenesis and MyoD down-regulate Sp1. A mechanism for the repression of GLUT1 during muscle cell differentiation

JAK2/STAT2/STAT3 are required for myogenic differentiation

Polypyrimidine Tract-Binding Protein 2 Binds to Selective, Intronic Messenger RNA and MicroRNA Targets in the Mouse Testis

Transforming growth factor β-activated kinase 1 (TAK1) Kinase Adaptor, TAK1-binding protein 2, plays dual roles in TAK1 signaling by recruiting both an activator and an inhibitor of TAK1 kinase in tumor necrosis factor signaling pathway

The authors wish to thank Dr. Julia von Maltzahn for donating the Pax7 antibody used in this study and for assistance with establishing a Pax7 IHC protocol for the laboratory.

The authors have no competing interests to declare.